Loading...
Market
BLINCYTO® sales growth in the first half of 2025?
2
Resolution / Starting Odds
Increase by more than 20% • 25%
Increase between 10% and 20% • 25%
Increase by less than 10% • 25%
No significant increase • 25%
Amgen's financial reports and sales data
Story
Amgen's BLINCYTO® Improves Survival in Pediatric B-Cell ALL: AALL1731 Results at ASH24
Dec 8, 2024, 02:04 PM
At the American Society of Hematology's (ASH) 2024 Annual Meeting (#ASH24), significant clinical trial results were presented, highlighting advancements in the treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). A key study presented by the Children's Oncology Group (COG) revealed that the addition of blinatumomab, marketed as BLINCYTO® by Amgen, to induction chemotherapy significantly improved disease-free survival in children with standard-risk B-ALL. The full results of the AALL1731 trial demonstrated enhanced survival rates when blinatumomab was added to chemotherapy regimens for newly diagnosed pediatric patients with B-cell precursor acute lymphoblastic leukemia.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%